A phase I study to evaluate the safety and tolerability of SX-682 in combination with PD-1 inhibitor as maintenance therapy for unresectable pancreatic adenocarcinoma

被引：5
|
作者：
Dunne, Richard Francis
Ullman, Nicholas A.
Belt, Brian A.
Ruffolo, Luis I.
Burchard, Paul
Hezel, Aram F.
Zittel, Jason
Wang, Wenjia
Ramsdale, Erika E.
Kaul, Vivek
Zebala, John
Linehan, David
机构：
[1] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA
[2] Univ Rochester, Med Ctr, Dept Surg, Rochester, NY 14642 USA
[3] Univ Rochester, Med Ctr, Dept Med, Div Gastroenterol, Rochester, NY 14642 USA
[4] Syntrix Pharmaceut, Auburn, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS631
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS631
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Phase I Study to Evaluate the Safety and Tolerability of SX-682 in Combination with anti-pd1 as Maintenance Therapy for Unresectable Pancreatic Adenocarcinoma
    Ullman, Nicholas A.
    Dunne, Richard
    Ruffolo, Luis
    Burchard, Paul R.
    Dave, Yatee
    Belt, Brian
    Georger, Mary
    Kaul, Vivek
    Hezel, Aram
    Wang, Wenjia
    Yeh, Jen Jen
    Zittel, Jason
    Massey, John
    Zebala, John
    Linehan, David
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 524 - 524
  • [2] An Update On The Phase I Study to Evaluate the Safety and Tolerability of SX-682 in Combination with Anti-PD1 as Maintenance Therapy for Unresectable Pancreatic Adenocarcinoma
    Ullman, Nicholas A.
    Dunne, Richard
    Mulkerin, Daniel
    Ruffolo, Luis
    Burchard, Paul
    Byrne, Matthew
    Georger, Mary
    Hezel, Aram
    Zittel, Jason
    Wang, Wenjia
    Ramsdale, Erika
    Kaul, Vivek
    Zebala, John
    Linehan, David
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S23 - S23
  • [3] Determining Safety and Tolerability of SX-682 in Combination with Anti-PD1 as Maintenance Therapy for Unresectable Pancreatic Adenocarcinoma, A Phase I Study
    Ullman, Nicholas A.
    Dunne, Richard
    Belt, Brian
    Ruffolo, Luis
    Burchard, Paul R.
    Georger, Mary
    Mulkerin, Daniel
    Hezel, Aram
    Zittel, Jazon
    Wang, Wenjia
    Ramsdale, Erika
    Kaul, Vivek
    Zebala, John
    Linehan, David
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S66 - S66
  • [4] Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti-PD-1 therapy
    Patel, Sapna Pradyuman
    Dimou, Anastasios
    Victor, Adrienne I.
    Mooradian, Meghan
    Buchbinder, Elizabeth Iannotti
    Hernandez-Aya, Leonel Fernando
    Prieto, Peter A.
    Cohen, Justine Vanessa
    Flaherty, Keith
    Kahn, Stuart
    Schuler, Aaron
    Maeda, Dean
    Zebala, John
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] A phase I study to evaluate the safety of trigriluzole (BHV-4157) in combination with PD-1 blocking antibodies.
    Silk, Ann W.
    Berman, Robert
    Coric, Vlad
    Ruggiero, Laura
    Reitz, Allen B.
    Shih, Weichung
    Kane, Michael P.
    Mehnert, Janice M.
    Pelletier, Jeffrey C.
    Zloza, Andrew
    Goydos, James Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [6] PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report
    Zhang, Hong-Qiang
    Huang, Chang-Zhi
    Wu, Jing-Yu
    Wang, Zhen-Ling
    Shao, Yu
    Fu, Zan
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (14) : 4669 - 4675
  • [7] PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report
    Hong-Qiang Zhang
    Chang-Zhi Huang
    Jing-Yu Wu
    Zhen-Ling Wang
    Yu Shao
    Zan Fu
    World Journal of Clinical Cases, 2022, (14) : 4669 - 4675
  • [8] A phase 1/2 study to evaluate the safety, tolerability, and preliminary efficacy of GP-2250 in combination with gemcitabine for advanced or metastatic pancreatic adenocarcinoma
    Kasi, Anup
    Iglesias, Jose Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study
    Yao, Junlin
    Zhu, Xudong
    Wu, Zhiheng
    Wei, Qing
    Cai, Yibo
    Zheng, Yu
    Hu, Xinyu
    Hu, Hong
    Zhang, Xiangyu
    Pan, Hongming
    Zhong, Xian
    Han, Weidong
    CANCER MEDICINE, 2022, 11 (19): : 3612 - 3622
  • [10] A phase I study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies
    Bendell, Johanna C.
    Manji, Gulam Abbas
    Pant, Shubham
    Lai, Dominic W.
    Colabella, Jill
    Berry, Wade
    Paoloni, Melissa Constance
    Grossman, William J.
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345